Navigation Links
TrovaGene, Inc. Obtains Exclusive License to Novel Mutations Associated with Prognosis and Chemotherapy Response in Leukemia
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- TrovaGene, Inc. (Pink Sheets: TROV), a developer of trans-renal molecular diagnostics,  today announced that it has obtained an exclusive worldwide license to mutations of the SF3B1 splicing factor, which have been shown to be associated with disease progression and chemotherapy response in patients suffering from chronic lymphocytic leukemia (CLL).

The findings have been published in the Dec 22 issue of BLOOD, the journal of the American Society of Hematology, in an article titled "Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness" (Rossi D. et al., Blood 118:6904-6908, 2011). A US patent application is pending.

Research results suggest that SF3B1 mutations represent important incremental diagnostic markers beyond TP53 disruptions and NOTCH1 mutations in CLL patients, and may also provide a therapeutic target for SF3B1 inhibitors, which are currently in pre-clinical development. Gianluca Gaidano and Davide Rossi at the Amedeo Avogadro University (Novara, Italy), lead the research team, in collaboration with their colleague Roberto Foa at the Sapienza University (Rome, Italy) that discovered the SF3B1 mutations.

"Since CLL is the most frequent type of leukemia in adults, the discovery of SF3B1 mutations in this disease will affect a large number of patients worldwide. In particular, SF3B1 mutations may contribute to the early identification of patients destined to fail standard treatment, who instead might benefit from more aggressive therapeutic strategies. Future goals in SF3B1 research include the development of a robust molecular assay for diagnosis, and the exploitation of SF3B1 as a therapeutic target for this leukemia," stated Gianluca Gaidano.

<
'/>"/>
SOURCE Trovagene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. DuPont Obtains Biotechnology Endorsement for Pioneer(R) Brand Products
3. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
4. China Sky One Medical, Inc. Obtains Production Rights for Nine New Drugs
5. NeoStem Obtains Exclusive Worldwide License to Innovative Stem Cell Technology and Applications for Anti-Aging Skin Rejuvenation Therapies
6. Mindset BioPharmaceuticals (USA) Inc Obtains Notice of Allowance for European Patent Related to Use of Insulin Sensitizers in Senile Dementia, Dementia and Memory Loss
7. Sinovac Biotech Co. Ltd., Sinovacs Beijing Subsidiary, Obtains High-Tech Enterprise Status
8. Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical
9. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
10. China Sky One Medical, Inc. Obtains SFDA Approvals for Geranium Ointment and Musk Liniment for Pain Relief
11. SemBioSys Genetics Inc. obtains up to $1.5 million in funding from AVAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... diseases that afflict skeletal growth through abnormalities in ... fetal stage and is caused by genetic mutations. ... factor receptor 3 (FGFR3) has been associated with ... a skeletal dysplasia that cause serious respiratory problems ... (ACH), which causes stunted growth and other complications ...
(Date:9/18/2014)... Scientists at USC have developed a new microscopy ... in living animals at higher-than-ever resolution. , Dubbed ... allows imaging resolutions that are an order of ... insights into the behavior of biomolecules at the ... Sept. 18 by Nature Communications , the ...
(Date:9/18/2014)... Silicon-valley Electronic Data Capture (EDC) provider ... , the latest addition to Clinovo’s CRO Partnership Program. ... (CRO) Program, Clinovo further expands its global reach to ... training, we are now able to build studies on ... can also rely on Clinovo to fully support the ...
(Date:9/18/2014)... Whitehouse Laboratories is pleased to announce that ... has acquired an additional 4,000 square feet of dedicated ... adjacent to its current package testing facility. The official ... Whitehouse Labs is in the process of upgrading the ... testing. The prime location enables Whitehouse Labs to immediately ...
Breaking Biology Technology:Researchers use iPS cells to show statin effects on diseased bone 2Researchers use iPS cells to show statin effects on diseased bone 3Scientists pioneer microscopy technique that yields fresh data on muscular dystrophy 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 2Digitaliza TXT Joins Clinovo’s CRO Partnership Program, Bringing Its Open Source EDC System, ClinCapture to Latin America 3Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4
... of Pittsburgh School of Dental Medicine are piecing together ... to novel nanoscale approaches to developing biomaterials. The findings ... of the National Academy of Sciences . Dental ... and combines high hardness with resilience, said Elia Beniash, ...
... NeoStem, Inc. (NYSE Amex: NBS ) ("NeoStem" ... focus on cell based therapeutics development, today announced that ... Program (PRMRP) of the Office of the Congressionally Directed ... be applied towards funding the Company,s VSEL™ Technology. This ...
... testing within the pharmaceutical and cosmetic industries and companies ... their products are safe to use. Research published in ... demonstrates that the response of laboratory grown human cells ... or non-sensitizing, and can even predict the strength of ...
Cached Biology Technology:NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 2NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 3NeoStem Announces the Receipt of Over $1,700,000 in DOD Funding for its VSEL™ Technology Being Developed to Treat Osteoporosis 4Cell-based alternative to animal testing 2
(Date:9/17/2014)... New research from the Copenhagen Centre for Social Evolution ... evolutionary theory that birth weight and -length can partially ... disorders such as autism and schizophrenia later in life. ... births, and subsequent hospital diagnoses for up to 30 ... factors. The study is published today in the ...
(Date:9/17/2014)... obtained the first partial genome sequence of an ancient ... the site of the Montsoriu Castle in Girona, the ... related to today,s Iberian pig. Researchers also discard the ... pigs. , The study, published in Heredity , ... and particularly on that of the Iberian breed, considered ...
(Date:9/17/2014)... retinoblastoma protein gene are a leading cause of eye ... fruit fly eyes to unlock the secrets of this ... on the cover of the current issue of the ... researchers provide the first detailed examination of a set ... cancer gene, said Irina Pushel, MSU undergraduate and co-author. ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Iberian pig genome remains unchanged after 5 centuries 2Abnormal properties of cancer protein revealed in fly eyes 2
... North Grafton, Mass., August 10, 2011 Second graders ... to maintain their reading skills during the dog days of ... Cummings School of Veterinary Medicine at Tufts University. In ... second-grade students with a range of reading aptitudes and attitudes ...
... structure of a complex formed when a protein binds ... how an antibiotic-producing organism controls resistance to its own ... antibiotic producers regulate export to prevent self-toxicity. , The ... complex and highly regulated process, not least because the ...
... , Invasive species cost an estimated $1.4 trillion annually ... second only to habitat loss as a threat to ... invasive species, the question of why some species are ... Dr. Alison Bennett and Dr. Sharon Strauss at the ...
Cached Biology News:Days spent reading to dogs during summer may help avoid decline of reading skills 2Student brings home new expertise to answer question in antibiotic resistance 2Student brings home new expertise to answer question in antibiotic resistance 3Waging war on invasive plant species: Effects of invasives persist even after removal 2
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
... DeCypher combines enterprise-scale sequence analysis software with the ... analyses. With DeCypher, you can perform searches like ... vs NCBI NT database in under 6 days ... genomic DNA Use HMM analysis to ...
... Reagent A: MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrasodium bromide), 50mg/vial. ... is cleaved by living cells to yield ... requires active mitochondria, and even freshly dead ... MTT. Reagent A is a component of ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: